Importantly, the inhibition of AhR successfully restores a pro-inflammatory, anti-tumor macrophage phenotype in IDH-mutant gliomas, and combining AhR inhibitors with anti-PD-L1 immunotherapy synergistically enhances therapeutic outcomes [76]. The gene discussed is AHR; the disease is central nervous system cancer.